Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 5:37:1-4.
doi: 10.1016/j.jdcr.2023.04.025. eCollection 2023 Jul.

Trimethoprim/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: A series of 16 cases

Rahul Masson  1 , Justine Seivright  2 , Terri Shih  3 , Richard G Bennett  4   5   6 , Marcia Hogeling  6 , Vivian Y Shi  7 , Jennifer L Hsiao  4
Affiliations
Case Reports

Trimethoprim/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: A series of 16 cases

Rahul Masson et al. JAAD Case Rep. .
No abstract available

Keywords: cephalexin; combination therapy; efficacy; hidradenitis suppurativa; outcomes; safety; treatment; trimethoprim/sulfamethoxazole.

PubMed Disclaimer

Conflict of interest statement

Dr Hogeling has been an investigator for Celgene and Amgen. Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Dr Hsiao is on the Board of Directors for the Hidradenitis Suppurativa Foundation, has served as a consultant for Aclaris, Boehringer Ingelheim, Novartis, and UCB, and has served as a consultant and speaker for AbbVie. There was no financial transaction for the preparation of this manuscript. All other authors report no conflicts of interest.

References

    1. Alikhan A., Sayed C., Alavi A., et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hid adenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101. doi: 10.1016/j.jaad.2019.02.068. - DOI - PMC - PubMed
    1. Hendricks A.J., Hsiao J.L., Shi V.Y. A comprehensive guide to Hid adenitis Suppurativa. Elsevier; 2022. Overview and comparison of hidradenitis suppurativa management guidelines; pp. 130–144. - DOI
    1. Mendonça C.O., Griffiths C.E.M. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa: hidradenitis suppurativa therapy. Br J Dermatol. 2006;154(5):977–978. doi: 10.1111/j.1365-2133.2006.07155.x. - DOI - PubMed
    1. van der Zee H.H., Boer J., Prens E.P., Jemec G.B.E. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143–147. doi: 10.1159/000228337. - DOI - PubMed
    1. Bessaleli E., Scheinfeld N. Clostridium difficile arising in a patient with hidradenitis suppurativa on clindamycin and rifampin. Dermatol Online J. 2018;24(5) doi: 10.5070/D3245040147. 13030/qt3x20x5rj. - DOI - PubMed

Publication types

LinkOut - more resources